

What is claimed is:

1. A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of said salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
2. A medicament according to claim 1 which is a pharmaceutical composition comprising a mixture of effective amounts of (A) and (B), optionally together with a pharmaceutically acceptable carrier.
3. A medicament according to claim 1, in which (A) is formoterol fumarate dihydrate.
4. A medicament according to claim 2, in which (A) is formoterol fumarate dihydrate.
5. A medicament according to claim 1, which is an inhalable aerosol comprising a mixture of (A) and (B) in solution or dispersion in a propellant, or a combination of an aerosol containing (A) in solution or dispersion in a propellant with an aerosol containing (B) in solution or dispersion in a propellant.
6. A medicament according to claim 5, in which (A) or (B), or (A) and (B), are in dispersion in the propellant, which is a halogen-substituted hydrocarbon.
7. A medicament according to claim 6, in which (A) or (B), or each of (A) and (B), has an average particle diameter of up to 10 $\mu$ m.
8. A medicament according to claim 1, which is an inhalable nebulizable composition comprising a dispersion of (A) and (B) in an aqueous, organic or aqueous/organic medium or a combination of a dispersion of (A) in said medium with a dispersion of (B) in said medium.
9. A medicament according to claim 1, which is an inhalable dry powder comprising finely divided (A) or (B), or finely divided (A) and (B), optionally together with a pharmaceutically acceptable carrier in finely divided form.
10. A medicament according to claim 9, in which the carrier is present and is a saccharide.

11. A medicament according to claim 10, in which the carrier is lactose.
12. A medicament according to claim 9, in which (A) or (B), or each of (A) and (B), has an average particle diameter up to 10  $\mu\text{m}$ .
13. A medicament according to claim 1, in which the weight ratio of (A) to (B) is from 2:1 to 1:2000.
14. A medicament according to claim 13, in which said ratio is from 1:10 to 1:25.
15. A medicament according to claim 2, in which the weight ratio of (A) to (B) is from 1:10 to 1:25.
16. A medicament according to claim 2, which is a dry powder in a capsule, the capsule containing from 3 to 36  $\mu\text{g}$  of (A) as formoterol fumarate dihydrate, from 25  $\mu\text{g}$  to 800  $\mu\text{g}$  of (B) and a pharmaceutically acceptable carrier in an amount to bring the total weight of dry powder per capsule to between 5 mg and 50 mg.
17. A medicament according to claim 2, which is a dry powder comprising, by weight, from 3 to 36 parts of (A) as formoterol fumarate dihydrate, from 25 to 800 parts of (B) and 2164 to 24972 parts of a pharmaceutically acceptable carrier.
18. A method of treating an inflammatory or obstructive airways disease which comprises administering to a subject in need of such treatment effective amounts of (A) as defined in claim 1 and (B) as defined in claim 1.
19. A method of treating an inflammatory or obstructive airways disease which comprises administering to a subject in need of such treatment an effective amount of a medicament according to claim 2.
20. A pharmaceutical kit comprising (A) as defined in claim 1 and (B) as defined in claim 1 in separate unit dosage forms, said forms being suitable for administration of (A) and (B) in effective amounts, together with one or more inhalation devices for administration of (A) and (B).